Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 01)
Doxazosin
Product Images NDC 50090-3987
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-3987). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Doxazosin Tablets (A308818e E36c 4431 Bf51 274650c38cb0 02)
This text seems to present results of three studies (1, 2, and 3) evaluating the efficacy of dorazosin in reducing symptoms of benign prostatic hyperplasia (BPH). The studies employed different titration methods and durations for doses of either placebo or dorazosin (4mg or 8mg). The efficacy was rated through the AUA and Boyarsky questionnaires, using mean scores and change in endpoint. The text also mentions a significant improvement in the mean change in symptoms of patients who received dosages of 8mg compared to placebo.*
Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 03)
Label Image (Lbl500903987)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
